As significant numbers of acute myeloid leukemia (AML) patients are still refractory to
conventional therapies or experience relapse, immunotherapy using T cells expressing …

Current therapeutic regimens for acute myeloid leukaemia (AML) are still associated with
high rates of relapse. Immunotherapy with T‐cells genetically modified to express chimeric …

Induction treatments for acute myeloid leukemia (AML) have remained largely unchanged
for nearly 50 years, and AML remains a disease of poor prognosis. Allogeneic …

The absence of cancer-restricted surface markers is a major impediment to antigen-specific
immunotherapy using chimeric antigen receptor (CAR) T cells. For example, targeting the …

Current therapies for acute myeloid leukemia are associated with high failure and relapse
rates. Adoptive immunotherapies, which have shown promise in the treatment of …

Background Successful development of chimeric antigen receptor (CAR) T cell
immunotherapy for children and adults with relapsed/refractory acute myeloid leukemia …

Chimeric antigen receptor (CAR) T cell therapy for the treatment of acute myeloid leukemia
(AML) has the risk of toxicity to normal myeloid cells. CD7 is expressed by the leukemic …

Many patients with acute myeloid leukemia (AML) are incurable with chemotherapy and may
benefit from novel approaches. One such approach involves the transfer of T cells …

Acute myeloid leukemia (AML) is a kind of a malignant hematologic tumor caused by
uncontrolled repopulation of myeloid hematopoietic stem cells (HSCs). Current therapeutic …

Background Paediatric acute myeloid leukaemia (AML) is characterized by poor outcomes
in patients with relapsed/refractory disease, despite the improvements in intensive standard …